KALV - KalVista Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$28.67
DETAILS
HIGH:
$32.00
LOW:
$27.00
MEDIAN:
$27.00
CONSENSUS:
$28.67
UPSIDE:
6.19%
About KalVista Pharmaceuticals, Inc. (https://www.kalvista.com)
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Benjamin L. Palleiko | Chief Executive Officer & Director | 1966 | $1,150,108 USD |
| Paul K. Audhya | Chief Medical Officer | 1972 | $773,445 USD |
| Christopher Yea | Chief Development Officer | 1964 | $708,532 USD |
| Brian Piekos | Chief Financial Officer | 1975 | $638,486 USD |
| Bilal Arif | Chief Operating Officer | 1972 | $572,458 USD |
| Brian Krex | General Counsel | 1968 | – |
| Christopher L. Hamblett | Senior Vice President of Corporate Development | – | – |
| Jarrod Aldom | Vice President of Corporate Communications | – | – |
| Linea Aspesi | Chief People Officer | 1970 | – |
| Rachel Morten | Senior Vice President of Regulatory Affairs & QA | – | – |
| Ryan Baker | Head of Investor Relations | – | – |